{"uid":"cap_HdqNsBR_Y3xVOij02EpEo","slug":"clinicalintelpulse-mechanism-of-action-map-f26b215f","name":"ClinicalIntelPulse Mechanism-of-Action Map","description":"Drug mechanism-of-action + molecular target landscape for any disease — targets in active trials, approved agents by MOA, crowded vs novel mechanisms and first-in-class openings, with key publications. Worldwide. For drug-discovery and VC agents.","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"condition":{"type":"string"},"mechanism":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"query_summary":{"condition":"Multiple Sclerosis","mechanism":null},"key_publications":[{"year":"2024","title":"BTK inhibitors in progressive MS — mechanisms and clinical data","journal":"Nature Reviews Neurology"}],"mechanism_landscape":{"white_spaces":["Progressive MS neuroprotection","Remyelination","CNS innate immunity","Biomarker-stratified precision approaches"],"crowded_spaces":["Anti-CD20 (3 approved, 2 in pipeline)","S1P modulators (4 approved)","Natalizumab analogues"],"approved_mechanisms":[{"moa":"Anti-CD20 (B cell depletion)","drugs":["Ocrelizumab","Ofatumumab","Ublituximab"],"notes":"Dominant mechanism for RRMS — 3 approved"},{"moa":"S1P receptor modulator","drugs":["Fingolimod","Siponimod","Ozanimod","Ponesimod"],"notes":"Oral DMT — 4 approved; class mature"},{"moa":"BTK inhibitor","drugs":[],"notes":"No approvals yet — 6 agents in Phase 2/3"}],"pipeline_mechanisms":[{"moa":"BTK inhibition (CNS-penetrant)","phase":"PHASE3","agents":["Fenebrutinib (Roche)","Tolebrutinib (Sanofi)","Evobrutinib (Merck)"],"crowding":"Moderate (3 Phase 3)","differentiation":"Targets microglial activation — may address progressive MS unlike existing agents"},{"moa":"Remyelination (opioid receptor modulation)","phase":"PHASE2","agents":["Opicinumab (Biogen)"],"crowding":"Low","differentiation":"Novel — no approved remyelinating agents"}]},"drug_discovery_implications":"BTK inhibition is the most clinically advanced novel mechanism. CNS penetration and microglial targeting differentiate from older agents. Progressive MS remains the largest unmet need.","first_in_class_opportunities":["BTK inhibitors for progression (if Phase 3 data positive)","Remyelinating agents (no approved class)"]}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.2","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.2/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.2","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.2","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_Ony2gW8QmruAnKKSKKsJ3","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.2","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns the drug mechanism-of-action and molecular target landscape for a disease, including targets in active trials, approved agents by MOA, crowded vs. novel mechanisms, first-in-class openings, and key publications.","exampleAgentPrompt":"Can you pull the full mechanism-of-action and molecular target landscape for non-alcoholic steatohepatitis — I want to see which targets are active in trials, what MOAs are already crowded with approved drugs, and where there are first-in-class openings?","exampleUseCases":[{"title":"Identify underdeveloped targets in oncology","prompt":"Help me map out the mechanism landscape for triple-negative breast cancer. I need to see which molecular targets have active clinical trials, which drug classes are already saturated with approvals, and where there might be real white space for a novel first-in-class approach."},{"title":"Assess MOA saturation in cardiology","prompt":"Can you show me the drug target landscape for heart failure with preserved ejection fraction? I want to understand which mechanisms are being pursued in Phase 2 and Phase 3 trials right now, compare that to what's already approved, and identify any gaps where we could have a competitive advantage with a new MOA."},{"title":"Find emerging targets in neurodegenerative disease","prompt":"I'm looking at Parkinson's disease therapeutics and need a clear picture of the molecular target space. Show me what's in active trials, which mechanisms already have approved agents, and highlight any mechanisms that are being explored but don't have drugs on the market yet."}],"resultDescription":"A structured landscape of molecular targets and drug mechanisms for the queried disease, including: which targets have drugs in active clinical trials, approved agents organized by MOA, identification of overcrowded vs. novel mechanisms, first-in-class whitespace opportunities, and links or citations to key supporting publications. Worldwide scope.","failureModes":["Unknown or ambiguous disease name returns an empty or error response","Very rare diseases with minimal trial activity may return sparse target data","Highly novel targets not yet in registered trials will be absent from the map","Rate limiting or payment failure (x402) if USDC balance is insufficient","Stale data if underlying trial registries have not been recently synced"],"whenToPreferThis":"Use this endpoint when you need a strategic MOA-level view of a disease space — specifically to understand which molecular targets are pursued in trials, which drug classes are saturated, and where first-in-class or best-in-class opportunities exist. Prefer this over a general pipeline endpoint when the primary question is about mechanism whitespace or target biology rather than company-level competitive intelligence or specific trial design details.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-14T00:43:31.957Z","isFirstParty":false}